How Is the HPV Test Done? A Step-by-Step Explanation

An HPV test detects genetic material from human papillomavirus in cells collected from the cervix, and the procedure itself takes only a few minutes during a routine visit. A clinician inserts a small brush or swab into the vaginal canal, gently rotates it against the cervix to pick up surface cells, and sends the sample to a lab where molecular techniques identify whether high-risk HPV strains are present. The test can also be done at home using a self-collection kit, though the standard clinical version remains the most widely used approach. What makes the test powerful is not just the collection but what happens afterward in the laboratory, and understanding each step helps make sense of what the results actually mean.

The Clinical Collection

If you are having the HPV test done during a clinic visit, the physical experience is very similar to a Pap smear, and in many cases the two are done at the same time from the same sample. You lie back on an exam table with your feet in stirrups while a clinician inserts a speculum to hold the vaginal walls open. A small brush or spatula is then rotated gently against the cervix to gather cells from its surface and the opening of the cervical canal. The whole collection takes roughly 30 seconds to a minute.

The collected cells are either rinsed into a vial of liquid preservative or transferred onto a slide. Most modern screening programs use liquid-based collection because the same vial can be used for both cytology (a Pap smear) and HPV molecular testing. Liquid preservative media keep the cells and their DNA stable during transport to the lab. Studies have validated several of these media, confirming that storage conditions do not compromise the accuracy of HPV detection downstream.¹

The procedure is not painful for most people, though some find the speculum uncomfortable. Mild spotting afterward is normal and resolves quickly. Your provider may ask you to avoid vaginal intercourse, douching, or using tampons for a day or two before the appointment, since these can reduce the number of cells available for collection.

Self-Collection at Home

A growing alternative to the clinical visit is self-sampling, where you collect your own vaginal sample at home and mail it to a lab. Self-collection typically uses a long swab or small brush that you insert into the vagina, rotate a few times, and then place into a transport tube. No speculum is needed, and you do not need to reach the cervix itself. Vaginal cells shed from the cervix collect along the vaginal walls, so a vaginal swab picks up enough HPV DNA for reliable testing.

A systematic review covering 38 studies found that the vast majority reported self-collected specimens had sensitivity and specificity comparable to clinician-collected samples, with good diagnostic agreement between the two methods.² In one study directly comparing the two approaches, self-sampling showed a concordance rate of about 90% with clinician sampling, and all participants found the self-sampling procedure easy to perform.³

Comfort is a major reason self-sampling is gaining traction. Women consistently report lower levels of pain, embarrassment, and anxiety when collecting their own sample compared to having a clinician perform the collection.⁴ One study found that about 71% of women preferred self-sampling because it was more comfortable, and about 56% because it caused less embarrassment.⁵ Even urine-based HPV sampling has been explored, with psychological distress significantly lower for both urine and self-vaginal methods compared to the traditional Pap test.⁶

Self-sampling does have a limitation: because you are not obtaining cells directly from the cervix, the sample cannot be used for a Pap smear. If your HPV result comes back positive from a self-collected sample, you will still need to visit a clinic for follow-up cytology or colposcopy. Self-collection works best as a first-pass screening tool, especially for people who might otherwise skip screening altogether.

What Happens in the Lab

Once your sample arrives at the laboratory, technicians are not looking at cells under a microscope (that is the Pap smear side of things). Instead, the HPV test uses molecular techniques to find the virus’s genetic material. There are two main approaches, and which one is used depends on the testing platform your lab runs.

The first and historically most common approach is HPV DNA testing. The lab extracts DNA from your sample and checks whether it matches known high-risk HPV types. Early versions used a method called signal amplification, where a chemical probe binds to HPV DNA and produces a detectable signal if a match is found. The Hybrid Capture 2 assay, which became the first FDA-approved HPV test in 2003, works this way.⁷ Newer platforms use PCR-based amplification, which copies any HPV DNA present in the sample billions of times over so that even tiny amounts become detectable. Real-time PCR systems can simultaneously identify and quantify multiple high-risk HPV types, including types 16, 18, 31, 33, 35, 39, 45, 52, and 58.⁸

The second approach is HPV mRNA testing. Rather than looking for the virus’s DNA blueprint, this method detects messenger RNA produced when the virus’s cancer-driving genes (E6 and E7) are actively being read by your cells. The logic is that the presence of DNA alone tells you an infection exists, while mRNA activity tells you the infection is doing something potentially dangerous. mRNA tests tend to be somewhat less sensitive than DNA tests but considerably more specific, meaning they produce fewer false alarms. One meta-analysis found that mRNA testing had comparable sensitivity to DNA testing while being significantly better at correctly ruling out disease, particularly in women with borderline or mildly abnormal Pap results.⁹ In practical terms, mRNA testing used as a follow-up tool has been shown to cut unnecessary colposcopy referrals substantially.¹⁰

Modern labs process these tests on high-throughput automated platforms. The three most widely used systems can each handle roughly 260 to 300 samples in a single run, with turnaround times of about three to four hours per batch.¹¹ Your individual result typically comes back within one to three weeks, depending on the lab’s workload and shipping time.

Understanding Your Results

HPV test results are reported differently depending on the platform, but they generally fall into a few categories. The simplest result is negative or positive for high-risk HPV. A negative result means no high-risk HPV DNA or RNA was detected, and depending on your age and screening history, you likely do not need another test for three to five years.

A positive result means one or more high-risk HPV types were found. Some testing platforms go a step further and report whether the infection involves HPV 16 or HPV 18 specifically, because these two types cause the majority of cervical cancers. If your result is positive for HPV 16 or 18, guidelines generally recommend proceeding directly to colposcopy, a closer examination of the cervix using a magnifying instrument. If you test positive for a different high-risk type, you may first have a reflex Pap smear done on the same liquid sample to see whether any cell changes are present before deciding on next steps.¹²

An important thing to keep in mind: a positive HPV test does not mean you have cancer. Most HPV infections clear on their own within a year or two without ever causing cell changes. The test is designed to flag people who need monitoring, not to deliver a diagnosis. Even among women referred to colposcopy after a positive HPV screening result, only about a quarter were found to have a high-grade abnormality on biopsy in one large Australian study.¹³

What Happens After a Positive Result

Follow-up after a positive HPV test depends on whether cell abnormalities are also present. If your Pap smear (either done at the same visit or as a reflex test on your stored sample) shows normal cells, the standard approach is to repeat both tests in one year. If the HPV infection has cleared and cells still look normal at that point, you return to routine screening.

If the Pap smear shows abnormal cells, or if you test positive for HPV 16 or 18 regardless of cytology, colposcopy is the next step. During colposcopy, a clinician applies a mild vinegar solution to the cervix, which causes abnormal areas to turn white and become visible under magnification. If a suspicious area is spotted, a small tissue sample (biopsy) is taken and sent for pathology to determine whether precancerous changes are present and how advanced they are.

For women who test positive for high-risk HPV repeatedly but whose Pap smears remain normal or show only minor changes, ongoing surveillance through colposcopy is generally recommended. Research has shown that persistent HPV positivity itself warrants close follow-up, since the combination of a positive HPV result and even minor cytological changes carries enough risk to justify further evaluation.¹⁴

Why HPV Testing Has Overtaken the Pap Smear

For decades, the Pap smear was the cornerstone of cervical cancer prevention. It works by looking for abnormal cell shapes under a microscope, which requires a skilled cytotechnologist and is inherently subjective. HPV molecular testing flipped the approach: instead of looking for damage that has already happened to cells, it looks for the virus that causes the damage in the first place.

The performance difference is real. A large systematic review found that HPV DNA testing catches about 90% of high-grade cervical lesions, compared to roughly 73% for cytology at its usual threshold.¹⁵ A population-based study in China put the gap even wider, finding HPV testing sensitivity near 96% compared to 48% for cytology alone when screening for moderate-to-severe precancerous changes.¹⁶ That higher sensitivity is the reason major guidelines now endorse primary HPV testing as the preferred screening method.

The American Cancer Society updated its recommendation in 2020, stating that people with a cervix should begin screening at age 25 with primary HPV testing every five years as the preferred strategy through age 65.¹⁷ The U.S. Preventive Services Task Force offers slightly different options: for people aged 21 to 29, cytology alone every three years; for those 30 to 65, cytology every three years, HPV testing alone every five years, or co-testing every five years.¹⁸ The USPSTF also recommends against screening for those under 21, those over 65 with adequate prior screening, and those who have had a hysterectomy with cervix removal for reasons other than cancer or precancer.

Modeling studies support HPV-first screening on economic grounds as well. Primary HPV testing detects more cases of serious precancerous lesions than cytology alone while costing less over a three-year screening cycle.¹⁹

HPV Testing Beyond the Cervix

The standard HPV test was designed around cervical screening, but the virus causes cancers at other body sites too, and interest in testing for those is growing. HPV-related anal cancer, penile cancer, and oropharyngeal (throat) cancer are all linked to the same high-risk strains, and they affect both men and women.

For anal cancer screening, high-risk populations such as men who have sex with men and people living with HIV may be offered an anal HPV test. The sample collection is similar in concept to a cervical test: a clinician inserts a moistened swab into the anal canal, rotates it, and sends the collected cells for cytology and HPV DNA testing. Research supports adding an HPV test alongside anal cytology to improve screening accuracy for anal precancer.²⁰

Testing men for HPV at other sites is more complicated. There is no FDA-approved HPV test for men, and no standard screening recommendation exists. Researchers have explored blood-based biomarkers and oral rinse samples as ways to screen men for HPV-related cancers. One early clinical trial used a combination of HPV 16 antibody blood testing and oral rinse HPV DNA testing in middle-aged men. Among the participants flagged positive, one was diagnosed with an early-stage HPV-related throat cancer shortly after enrollment, and several others had HPV-associated anal dysplasia.²¹ These results are preliminary, and the lack of standardized testing methods and guidelines remains a significant barrier to routine male HPV screening.²²

How Vaccination Is Reshaping HPV Screening

As more people enter screening age having been vaccinated against HPV in childhood, the landscape of testing is shifting. HPV vaccines target the most dangerous strains, and in populations with good vaccine uptake, the number of high-grade cervical abnormalities has already dropped. Data from Slovenia’s national vaccination program showed that even with about 50% vaccine coverage, the rate of moderate-to-severe precancerous lesions in the vaccinated cohort fell by roughly 42%.²³

This declining disease prevalence creates a real statistical problem for screening programs. When the virus and its associated lesions become rarer in a population, any screening test produces proportionally more false positives relative to true positives. The positive predictive value of the test drops, meaning a larger share of people flagged positive will turn out to have nothing wrong after follow-up colposcopy and biopsy. Researchers have flagged this concern specifically, noting that the strong dependence of cytological abnormalities on underlying lesion prevalence makes the traditional Pap smear particularly vulnerable to this erosion, and that screening algorithms in vaccinated populations may need adjustment.²⁴

What this means for you practically: vaccination does not eliminate the need for screening. Not all HPV types are covered by the vaccine, and not everyone was vaccinated at the ideal age. But the screening intervals and follow-up thresholds you encounter may look different in the coming decade, particularly if you were vaccinated. Several countries are already exploring whether vaccinated cohorts can be screened less frequently or starting at a later age, and the shift toward primary HPV testing over cytology partly reflects this evolving math. Screening programs built around detecting the virus itself are better positioned to remain useful as the prevalence of that virus declines, because HPV DNA and mRNA tests maintain high sensitivity regardless of how common the infections are in the population.

DNA Versus mRNA Testing in Practice

If you are wondering whether it matters which type of HPV test your lab uses, the honest answer is: for primary screening it usually does not make a practical difference, but for follow-up decisions it might. HPV DNA tests cast a wide net. They are extremely sensitive, catching nearly all high-risk infections, but they also flag infections that are transient and would never lead to disease. That high sensitivity is exactly what you want in a first-pass screen.

Where mRNA testing shows its strength is as a triage tool after an initial positive HPV result. Because the test only fires when the virus’s cancer-promoting genes are actively being expressed, it is better at distinguishing infections that are progressing from those that are clearing on their own. One study found that DNA-based methods had very high negative predictive value, meaning they are excellent at ruling out disease when negative.²⁵ But among people who tested positive, the mRNA-based assay was better at identifying who actually had clinically meaningful disease, sparing many from unnecessary invasive follow-up.

In daily clinical workflow, you are unlikely to get a choice between DNA and mRNA testing. The lab your provider sends samples to typically runs one platform. But if your provider mentions that your test was an “Aptima” or “AHPV” test, that is an mRNA-based assay. If they mention “cobas” or “Hybrid Capture,” those are DNA-based. All are clinically validated and FDA-approved for their intended uses. The field is increasingly moving toward using DNA testing as the front door and reserving mRNA testing for the triage step, combining the wide net of one with the sharper focus of the other.